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Background
Several recent clinical trials showed that the antidiabetic
drug rosiglitazone is associated with an excess risk of
cardiovascular adverse events. In spite of its widespread
clinical application there is little information on its cel-
lular cardiac effects in larger mammals. In the present
study, therefore, concentration-dependent effects of rosi-
glitazone on action potential morphology and the
underlying ion currents were studied in canine hearts.
Methods
Standard microelectrode techniques, conventional whole
cell patch-clamp, and action potential voltage-clamp
techniques were applied in enzymatically dispersed ven-
tricular cells.
Results
At concentrations ≥ 10 µM rosiglitazone decreased the
amplitude of phase-1 repolarization, reduced the maxi-
mum velocity of depolarization and caused depression
of the plateau potential. These effects developed rapidly
and were readily reversible upon washout. Rosiglitazone
suppressed several transmembrane ion currents in a con-
centration-dependent manner under conventional voltage-
clamp conditions and altered their kinetic properties. The
EC50 value for this inhibition was 25.2 ± 2.7 µM for the
transient outward K+ current (Ito), 72.3 ± 9.3 µM for the
rapid delayed rectifier K+ current (IKr), and 82.5 ± 9.4 µM
for the L-type Ca2+ current (ICa) with Hill coefficients
close to unity. The inward rectifier K+ current (IK1)
was not affected by rosiglitazone up to concentrations of
100 µM. Suppression of Ito, IKr, and ICa was confirmed
under action potential voltage-clamp conditions as well.
Conclusions
The observed alterations in the densities and kinetic
properties of ion currents may carry serious proarrhyth-
mic risk in case of overdose intoxication with rosiglita-
zone, especially in older diabetic patients having
multiple cardiovascular risk factors.
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